Financial Review: Mesoblast (NASDAQ:MESO) vs. AIM ... - ETF Daily …

2 days ago · 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 18.8% of Mesoblast shares are …

4%
OFF

Financial Review: Mesoblast (NASDAQ:MESO) Vs. AIM ... - ETF Daily …

2 weeks from now

2 days ago · 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 18.8% of Mesoblast shares are …

etfdailynews.com

07%
OFF

Analyzing Mesoblast (NASDAQ:MESO) & AIM ImmunoTech …

2 weeks from now

4 days ago · AIM ImmunoTech presently has a consensus price target of $2.75, suggesting a potential upside of 1,179.07%. Mesoblast has a consensus price target of $13.50, suggesting …

defenseworld.net

$20.97
OFF

Mesoblast (NASDAQ:MESO) Hits New 12-Month High - ETF Daily …

2 weeks from now

Jan 1, 2025 · Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high as $20.97 and last traded at $20.75, with a …

etfdailynews.com

32%
OFF

Is Mesoblast Ltd (MESO) A Hidden Value Trap? Unpacking The …

2 weeks from now

Aug 25, 2023 · One such stock that merits attention is Mesoblast Ltd (NASDAQ:MESO). Currently priced at $1.44, the stock recorded a loss of 12.32% in a day and a 3-month decrease of 58.41%.

yahoo.com

$0.28
OFF

Mesoblast (MESO) Stock Price, News & Analysis - MarketBeat

2 weeks from now

5 days ago · Mesoblast Limited (NASDAQ:MESO) issued its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating …

marketbeat.com

$17.02
OFF

Mesoblast (NASDAQ:MESO) Cut To Hold At Jefferies Financial …

2 weeks from now

Dec 25, 2024 · Shares of NASDAQ:MESO opened at $17.02 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a …

etfdailynews.com

4%
OFF

Mesoblast Limited (MESO) Upgraded To Buy: Here's What You

2 weeks from now

Dec 15, 2022 · Earnings Estimate Revisions for Mesoblast Limited For the fiscal year ending June 2023, this company is expected to earn -$0.48 per share, which is a change of 31.4% from the …

nasdaq.com

$2
OFF

Mesoblast Finally Gets Its Approval In GVHD: Where Now?

2 weeks from now

Dec 19, 2024 · Mesoblast Limited's Remestemcel-L has been approved for treating acute graft-versus-host disease, driving recent share price momentum and a potential market cap of $2 …

seekingalpha.com

$1.61
OFF

Mesoblast (NASDAQ:MESO) Downgraded To "Hold" Rating By …

2 weeks from now

Dec 23, 2024 · Mesoblast has a one year low of $1.61 and a one year high of $19.15. The business has a fifty day moving average price of $10.62 and a 200-day moving average price …

marketbeat.com

$14.63
OFF

Mesoblast (NASDAQ:MESO) Shares Gap Up - Should You Buy?

2 weeks from now

Dec 23, 2024 · Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $14.63, but opened at $15.72. …

marketbeat.com

$19.80
OFF

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?

2 weeks from now

Jan 2, 2025 · Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $19.80, but opened at …

marketbeat.com

1%
OFF

Mesoblast (NASDAQ:MESO) Trading Up 6.1% - What's Next?

2 weeks from now

Dec 26, 2024 · Mesoblast Limited (NASDAQ:MESO - Get Free Report) was up 6.1% during mid-day trading on Thursday . The company traded as high as $18.07 and last traded at $18.06. …

marketbeat.com

55%
OFF

Mesoblast (MESO) Competitors And Alternatives 2025 - MarketBeat

2 weeks from now

5 days ago · Intra-Cellular Therapies currently has a consensus price target of $97.23, indicating a potential downside of 23.55%. Mesoblast has a consensus price target of $13.50, indicating …

marketbeat.com

FAQs about Financial Review: Mesoblast (NASDAQ:MESO) vs. AIM ... - ETF Daily … Coupon?

Is Mesoblast Ltd (meso) a good value stock?

Value-focused investors constantly seek stocks priced below their intrinsic value. One such stock that merits attention is Mesoblast Ltd ( NASDAQ:MESO ). Currently priced at $1.44, the stock recorded a loss of 12.32% in a day and a 3-month decrease of 58.41%. Its fair valuation, as indicated by the GF Value, is $3.53. ...

How much did Mesoblast (meso) earn in a quarter?

Mesoblast Limited (NASDAQ:MESO) issued its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. The firm earned $2.14 million during the quarter, compared to analyst estimates of $2 million. ...

How many shares does Mesoblast limited have?

Mesoblast Limited has 147.32 million shares outstanding, while 130.7 million shares represent the free float, which is the volume of shares that can be freely traded on the NASDAQ stock exchange. Owning MESO shares involves the risk that one or more projects will fail, which may adversely affect the market value of these shares. ...

Are Mesoblast insiders buying or selling stock?

In the past three months, Mesoblast insiders have not sold or bought any company stock. 18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 1.43% of the stock of Mesoblast is held by institutions. ...

Does Mesoblast stock have a downside?

According to analysts, Mesoblast's stock has a predicted downside of -35.84% based on their 12-month stock forecasts. Has Mesoblast been downgraded by Wall Street analysts recently? Over the previous 90 days, Mesoblast's stock had 1 downgrade by analysts. What analysts cover Mesoblast? ...

What is the forecast for Mesoblast stock?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Mesoblast is $13.50, with a high forecast of $15.00 and a low forecast of $12.00. Should I buy or sell Mesoblast stock right now? ...